Roosevelt Investment Group Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 2.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,203 shares of the company’s stock after buying an additional 72 shares during the period. Roosevelt Investment Group Inc.’s holdings in Eli Lilly and were worth $269,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of LLY. Heritage Trust Co bought a new position in shares of Eli Lilly and during the first quarter worth about $135,000. Penserra Capital Management LLC increased its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the period. Crestwood Advisors Group LLC bought a new position in shares of Eli Lilly and during the first quarter worth about $179,000. Sandy Spring Bank increased its position in shares of Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after buying an additional 750 shares during the period. Finally, Coldstream Capital Management Inc. bought a new position in shares of Eli Lilly and during the first quarter worth about $200,000. Institutional investors own 75.77% of the company’s stock.

Shares of Eli Lilly and Company (LLY) traded up 2.489% during midday trading on Wednesday, reaching $80.505. The company’s stock had a trading volume of 2,588,339 shares. The stock has a 50-day moving average price of $81.83 and a 200-day moving average price of $81.93. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a market cap of $84.93 billion, a price-to-earnings ratio of 34.836 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.86 earnings per share. Equities research analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.65%. Eli Lilly and’s payout ratio is 90.04%.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/roosevelt-investment-group-inc-has-269000-stake-in-eli-lilly-and-company-lly/1531904.html.

A number of equities analysts have recently issued reports on the company. Jefferies Group LLC restated a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. BMO Capital Markets restated a “sell” rating and set a $73.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. BidaskClub downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Berenberg Bank restated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Finally, TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $87.92.

In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total value of $17,855,750.00. Following the completion of the transaction, the insider now owns 124,475,804 shares of the company’s stock, valued at $10,337,715,522.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock valued at $55,845,287 in the last quarter. 0.20% of the stock is owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.